**510(k) Summary - COBAS Integra Bicarbonate liquid**

| **Introduction** | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence |
| **Submitter name, address, contact** | Roche Diagnostics Corporation  
9115 Hague Rd  
Indianapolis IN 46250  
(317) 521-3831  
Contact person: Sherri L. Coenen  
Date prepared: June 13, 2003 |
| **Device Name** | Proprietary name: Roche Diagnostics COBAS Integra Bicarbonate liquid  
Common name: Enzymatic Bicarbonate Assay  
Classification name: enzymatic bicarbonate/carbon dioxide test system |
| **Device description** | The COBAS Integra Bicarbonate liquid is a ready-to-use liquid enzymatic assay with phosphoenolpyruvate carboxylase and malate dehydrogenase. A decrease in absorbance at 409 nm is proportional to the concentration of bicarbonate in the sample. |
| **Intended use** | The cassette COBAS Integra Bicarbonate liquid (CHOL2) contains an in vitro diagnostic reagent system intended for use on COBAS Integra systems for the quantitative determination of the bicarbonate \((\text{HCO}_3^-)\) concentration in human serum and plasma. |
| **Predicate Device** | We claim substantial equivalence to the currently marketed COBAS Integra Carbon Dioxide Assay. (K980996). |
The following table describes the similarities and differences between the COBAS Integra Bicarbonate liquid and the predicate device.

<table>
<thead>
<tr>
<th>Topic</th>
<th>COBAS Integra Carbon Dioxide (K980996)</th>
<th>COBAS Integra Bicarbonate liquid (Modified Device)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended Use</td>
<td>The cassette COBAS Integra Carbon Dioxide (CO2-S) contains an in vitro diagnostic reagent system intended for use on COBAS Integra systems for the quantitative determination of the carbon dioxide concentration in serum and plasma.</td>
<td>The cassette COBAS Integra Bicarbonate liquid (CO2-L) contains an in vitro diagnostic reagent system intended for use on COBAS Integra systems for the quantitative determination of the bicarbonate (HCO₃⁻) concentration in human serum and plasma.</td>
</tr>
<tr>
<td>Method</td>
<td>Enzymatic, colorimetric test</td>
<td>Same</td>
</tr>
<tr>
<td>Sample type</td>
<td>Human Serum and Plasma</td>
<td>Same</td>
</tr>
<tr>
<td>Measuring range</td>
<td>0 - 50 mmol/L</td>
<td>Same</td>
</tr>
<tr>
<td>Expected values</td>
<td>Anaerobic venous plasma or serum: 23 - 29 mmol/L</td>
<td>22 - 29 mmol/L</td>
</tr>
</tbody>
</table>
Ms. Sherri L. Coenen MT(ASCP)
Regulatory Affairs Consultant
Regulatory Submissions, Centralized Diagnostics
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, IN 46250-0457

Re: k031879
    Trade/Device Name: COBAS Integra Bicarbonate liquid
    Regulation Number: 21 CFR 862.1160
    Regulation Name: Bicarbonate/carbon dioxide test system
    Regulatory Class: Class II
    Product Code: KHS
    Dated: June 13, 2003
    Received: June 18, 2003

Dear Ms. Coenen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsma/main.html.

Sincerely yours,

Steven E. Gutman, M.D., M.B.A.
Director
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure
Indications for Use Statement

510(k) Number (if known): N/A

Device Name: COBAS Integra Bicarbonate liquid

Indications For Use:

The cassette COBAS Integra Bicarbonate liquid (CHOL2) contains an in vitro diagnostic reagent system intended for use on COBAS Integra systems for the quantitative determination of the bicarbonate (HCO₃⁻) concentration in human serum and plasma. Bicarbonate/carbon dioxide measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K031879

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use OR Over-The-Counter Use

(Optional Format 1-2-96)